Aspirin And Extended-release Dipyridamole Capsule, Extended Release
Product Images NDC 42571-274

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Aspirin And Extended-release Dipyridamole (NDC 42571-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cumulative Stroke Rate Figure (Aspirindipyridamole Figure1)

This is a table showing the cumulative stroke rate (%) for three different treatment groups over two months of follow-up. The treatment groups are identified as ASA, ER-DP, and ASA+ER-DP. ASA stands for aspirin, ER-DP stands for extended-release dipyridamole, and ASA+ER-DP represents a combination of the two treatments. The table indicates that the cumulative stroke rate was 15% for the ASA group, 10% for the ER-DP group, and 4% for the ASA+ER-DP group. The dosage regimen for all three treatments is not available.*

FDA Label Image

Aspirindipyridamole Lbl

FDA Label Image

Aspirin Structure (Aspirindipyridamole Strc2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.